Savara CMO Shift: CTMS Deal Flow Trigger

🚀 Battle Card: Savara Inc.

• Yasmine Wasfi, M.D., Ph.D., FCCP, Chief Medical Officer · 🔗 LinkedIn

• Leadership change at the C-suite level accelerates focus on late-stage trial efficiency and regulatory strategy → Source

• This Savara Inc. sales trigger signals urgency to offer clinical operations support as MOLBREEVI nears Phase 3 readout

• Capitalize on the Savara Inc. sales trigger with targeted CTMS demos

• Streamline Phase 3 trial enrollment and data management

• Optimize regulatory submission workflows amid accelerated timelines

• Primary: Clinical Trial Management System (CTMS) → Faster patient enrollment & centralized oversight

• Expansion: Regulatory Intelligence Platform → Reduced review cycles & compliance risk

• HQ: Langhorne, PA

• Employees: ≈ 100

• Rev: ≈ $10 M

• Website: savarapharma.com

🤼 Competitive Intel

• Medidata — Clinical Trial Management
• Unique edge: Deep analytics for trial forecasting
• Evaluated by CMO & Head of Clinical Ops for enrollment acceleration

• Veeva Systems — CTMS & eTMF
• Unique edge: Unified trial docs & real-time status
• Evaluated by VP Clinical Operations for global compliance

• Oracle — CTMS
• Unique edge: End-to-end trial automation at scale
• Evaluated by CIO & VP IT for integration with EHR

• PharmaLex — Regulatory Intelligence
• Unique edge: Expert local regulatory consultants
• Evaluated by CMO & Head of RA for submission support

• Informa Pharma Intelligence — Regulatory & Market Analytics
• Unique edge: Comprehensive drug pipeline data
• Evaluated by VP Strategy for competitive insights

✅ Do-Now Checklist

Next Step

🧠 Copy My Prompt for Personalized Cold Outreach

────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY   = ❑❑
OFFER_BRIEF   = ❑CTMS to accelerate Phase 3 trial enrollment❑
PROOF_METRIC  = ❑≈25% faster enrollment❑
CTA_STYLE     = ❑quick_call❑
TONE          = ❑friendly❑

────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME        = Yasmine
COMPANY     = Savara Inc.
DEPT        = ≈ TBD
SIZE        = ≈ TBD
BOTTLENECK  = streamline Phase 3 trial enrollment and data management
EVENT       = Chief Medical Officer (CMO) Transition
DETAIL      = Yasmine Wasfi promoted to CMO
PAIN        = streamline Phase 3 trial enrollment and data management
SRC         = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251017555130&div=41152219
SIM_CO      = ≈ TBD
WIN_METRIC  = ≈ TBD
NEXT_SIZE   = ≈ TBD
EMP_EST     = ≈ 100
REV_EST     = ≈ $10M

────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.

Validate any ≈ guesses via SRC.

EMAIL  (keep breaks):
Subject: ≈ TBD-person ≈ TBD

Yasmine—noticed your ≈ TBD team is ≈ TBD.

That’s when streamline Phase 3 trial enrollment and data management slows growth.

We helped ≈ TBD fix this with CTMS to accelerate Phase 3 trial enrollment.

Result: ≈ TBD.  
Quick call?

PS—next bottleneck hits ≈ TBD.

DM ≤45 words, TONE:
Saw your post about Yasmine Wasfi promoted to CMO — streamline Phase 3 trial enrollment and data management.  
CTMS to accelerate Phase 3 trial enrollment. ≈25% faster enrollment.  
Quick chat?